Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Sigma-Aldrich® Partners with Scripps Research Institute

Published: Friday, July 19, 2013
Last Updated: Friday, July 19, 2013
Bookmark and Share
The agreement marks first partnership of its kind between a research institution and reagents company.

Sigma-Aldrich announce a partnership with The Scripps Research Institute (TSRI) to fund research and provide immediate, day-of-publication access to TSRI researchers' discoveries for the synthesis and analysis of potential drugs. The partnership promises to eliminate months from the translation of cutting-edge chemistry into widespread applications for drug discovery.

The partnership includes six TSRI research labs led by Professors Phil Baran, Jin-Quan Yu, Benjamin Cravatt, Carlos Barbas, Phillip Dawson, and Nobel Laureate K. Barry Sharpless. TSRI will receive funds to be used to expand capacity for basic research.

TSRI approached Sigma-Aldrich to eliminate the delay between the invention of novel reagents and reliable, widespread access to those reagents for the translational research community. "The hurdles from bench to clinic, what the NIH calls the 'valley of death', are proving difficult to surmount, leaving numbers of potential therapeutic ideas trapped inside university doors. To clear these hurdles, it's critical to open a myriad of novel technologies, such as these from TSRI, to the whole translational research community," said Amanda Halford, Vice President, Academic Research at Sigma-Aldrich.

"This is the third major deal in our new targeted partnership strategy, following recent agreements with Janssen Pharmaceuticals and Bristol-Myers Squibb," said Scott Forrest, Vice President of Business Development at TSRI. "These multi-lab, multi-year alliances fund research and infrastructure in areas of mutual interest, creating a win-win situation for moving innovations into the marketplace. We are pleased to partner with the world's leading reagent company to accelerate the commercialization of new research tools for the scientific community."

Sigma-Aldrich and TSRI will partner to fund development of novel reagents from the six TSRI labs, which Sigma-Aldrich will commercialize exclusively via a master licensing agreement. This will allow unfettered access to new reagents by chemists and also scientists who do not have a background in chemical synthesis, which in the past limited their ability to implement novel reagents in their research.

Last year, TSRI and Sigma-Aldrich established a partnership to produce in bulk a toolkit of ten novel zinc-based salts discovered in the Baran lab, including the Baran difluoromethylation reagent that several large pharmaceutical companies immediately adopted for optimizing lead compounds.

"The partnership with TSRI will enable us to expand our portfolio through new innovations and product development," said Eric Green, Executive Vice President and President, Research at Sigma-Aldrich.  "We believe this partnership reinforces our strategy of broadening our research portfolio of innovative products and tools used by the translational research community."

Publications of new reagents developed in these six TSRI labs will include a Sigma-Aldrich product number for simple reference.

While a number of collaborative partnerships have emerged between academic institutions and pharmaceutical companies, this is the first partnership of its kind between a research institute and a reagents company.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sigma-Aldrich Stockholders Approve Merck Acquisition
The transaction, expected to close mid-2015, remains subject to the satisfaction of the closing conditions set forth in the merger agreement, including regulatory approvals.
Monday, December 08, 2014
SAFC Expands Continuous Flow Capabilities
Sigma-Aldrich custom manufacturing services business unit, SAFC® Commercial, has installed a new commercial-scale continuous flow reactor at its Sheboygan, WI facility.
Wednesday, May 21, 2014
Sigma Life Science to Distribute Olink Bioscience's Protein-Protein Interaction Assay
The products complement Sigma's antibody, RNAi and gene editing technologies.
Tuesday, February 12, 2013
Sigma-Aldrich Completes Acquisition of BioReliance
Sigma-Aldrich Corporation completes its acquisition of BioReliance Holdings, Inc. for $350 million in cash.
Wednesday, February 01, 2012
Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database
Sigma Life Science announces that its SAGE Labs initiative has partnered with Cofactor Genomics in an effort to sequence genomes for six of the most widely used strains of rat. Cofactor Genomics plans to generate and analyze sequence data using next generation sequencing systems, while SAGE Labs plans to provide the samples and to host a new, free public database at in late 2011.
Thursday, February 03, 2011
Sigma® Life Science Awarded Silver in Top Ten Innovations 2010
Company’s CompoZr® cell lines ranked second as The Scientist magazine unveils this year’s best life science innovations.
Monday, December 06, 2010
Plasticell Signs Technology Agreement with Sigma-Aldrich
Collaboration to produce novel turnkey solution for stem cell research.
Tuesday, November 30, 2010
Sigma® Life Science Enters Genetically Modified Cell Market
Sigma Life Science launches range of engineered cell lines exploiting CompoZr® zinc finger nuclease technology.
Monday, September 06, 2010
Sigma® Life Science and Switchgear Genomics to Co-Develop Simplified Novel MicroRNA Target Validation System
SwitchGear Genomics and Sigma’s lentiviral technology combined to simplify miRNA target validation, enabling researchers to investigate gene regulation.
Tuesday, August 10, 2010
Sigma-Aldrich Licenses from NeuroSurvival Technologies a Marker for Molecular Imaging of Apoptosis in Vivo
The marker, Apo-TRACE™, offers a breakthrough in advancing apoptosis-related research in a range of fields in biology and medicine.
Wednesday, February 27, 2008
Sigma-Aldrich Grants Pfizer Non-Exclusive Worldwide License to Use ddRNAi in Research Programs
The license enables Pfizer to undertake research activities throughout its global operations using ddRNAi technology.
Thursday, January 04, 2007
Sigma-Proligo Expands into Genopole® d'Evry Biopark
Sigma-Proligo provides researchers with high-quality oligonucleotides due to a high throughput synthesis platform.
Friday, October 20, 2006
Sigma-Aldrich Announces Service Provider for WGA Technology
Sigma announces MOgene as its first service provider of the GenomePlex® Whole Genome Amplification technology.
Wednesday, May 31, 2006
Sigma-Aldrich Sponsors Full-Text Article on High Content Viral Library Screens
The authors reported the creation of a lentiviral shRNA library to knock down genes for genome-wide screening.
Thursday, April 27, 2006
Scientists Publish Results on Sigma-Aldrich's shRNA Library in Cell
The publication reported the creation of a lentiviral shRNA library to knock down genes for genome-wide screening.
Thursday, April 13, 2006
Scientific News
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos